Since CD86 can activate not only effector T cells but also Treg cells, it is possible that in CLL, the tumor cells suppress the T‐cell immune response via the CD86‐Treg connection, and the anti‐tumor response capability of the immune system is reduced. This evidence concerns the gene CD86 and B-cell chronic lymphocytic leukemia.